Cargando…
Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples
A major obstacle for preclinical testing of Alzheimer’s disease (AD) therapies is the availability of translationally relevant AD models. Critical for the validation of such models is the application of the same approaches and techniques used for the neuropathological characterization of AD. Deposit...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735310/ https://www.ncbi.nlm.nih.gov/pubmed/31528297 http://dx.doi.org/10.1080/20010001.2019.1657768 |
_version_ | 1783450332528902144 |
---|---|
author | Urfer, Silvan R. Latimer, Caitlin S. Ladiges, Warren Keene, C. Dirk Benbow, Sarah Harrison, Benjamin Promislow, Daniel E.L. Kaeberlein, Matt Kraemer, Brian C Wang, Adrienne Guscetti, Franco Darvas, Martin |
author_facet | Urfer, Silvan R. Latimer, Caitlin S. Ladiges, Warren Keene, C. Dirk Benbow, Sarah Harrison, Benjamin Promislow, Daniel E.L. Kaeberlein, Matt Kraemer, Brian C Wang, Adrienne Guscetti, Franco Darvas, Martin |
author_sort | Urfer, Silvan R. |
collection | PubMed |
description | A major obstacle for preclinical testing of Alzheimer’s disease (AD) therapies is the availability of translationally relevant AD models. Critical for the validation of such models is the application of the same approaches and techniques used for the neuropathological characterization of AD. Deposition of amyloid-β 42 (Aβ42) plaques and neurofibrillary tangles containing phospho-Tau (pTau) are the pathognomonic features of AD. In the neuropathologic evaluation of AD, immunohistochemistry (IHC) is the current standard method for detection of Aβ42 and pTau. Although IHC is indispensable for determining the distribution of AD pathology, it is of rather limited use for assessment of the quantity of AD pathology. We have recently developed Luminex-based assays for the quantitative assessment of Aβ42 and pTau in AD brains. These assays are based on the same antibodies that are used for the IHC-based diagnosis of AD neuropathologic change. Here we report the application and extension of such quantitative AD neuropathology assays to commonly used genetically engineered AD models and to animals that develop AD neuropathologic change as they age naturally. We believe that identifying AD models that have Aβ42 or pTau levels comparable to those observed in AD will greatly improve the ability to develop AD therapies. Abbreviations: Alzheimer’s disease (AD); amyloid β 42 (Aβ42); phospho-Tau (pTau); immunohistochemistry (IHC) |
format | Online Article Text |
id | pubmed-6735310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-67353102019-09-16 Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples Urfer, Silvan R. Latimer, Caitlin S. Ladiges, Warren Keene, C. Dirk Benbow, Sarah Harrison, Benjamin Promislow, Daniel E.L. Kaeberlein, Matt Kraemer, Brian C Wang, Adrienne Guscetti, Franco Darvas, Martin Pathobiol Aging Age Relat Dis Technical Report A major obstacle for preclinical testing of Alzheimer’s disease (AD) therapies is the availability of translationally relevant AD models. Critical for the validation of such models is the application of the same approaches and techniques used for the neuropathological characterization of AD. Deposition of amyloid-β 42 (Aβ42) plaques and neurofibrillary tangles containing phospho-Tau (pTau) are the pathognomonic features of AD. In the neuropathologic evaluation of AD, immunohistochemistry (IHC) is the current standard method for detection of Aβ42 and pTau. Although IHC is indispensable for determining the distribution of AD pathology, it is of rather limited use for assessment of the quantity of AD pathology. We have recently developed Luminex-based assays for the quantitative assessment of Aβ42 and pTau in AD brains. These assays are based on the same antibodies that are used for the IHC-based diagnosis of AD neuropathologic change. Here we report the application and extension of such quantitative AD neuropathology assays to commonly used genetically engineered AD models and to animals that develop AD neuropathologic change as they age naturally. We believe that identifying AD models that have Aβ42 or pTau levels comparable to those observed in AD will greatly improve the ability to develop AD therapies. Abbreviations: Alzheimer’s disease (AD); amyloid β 42 (Aβ42); phospho-Tau (pTau); immunohistochemistry (IHC) Taylor & Francis 2019-09-03 /pmc/articles/PMC6735310/ /pubmed/31528297 http://dx.doi.org/10.1080/20010001.2019.1657768 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Technical Report Urfer, Silvan R. Latimer, Caitlin S. Ladiges, Warren Keene, C. Dirk Benbow, Sarah Harrison, Benjamin Promislow, Daniel E.L. Kaeberlein, Matt Kraemer, Brian C Wang, Adrienne Guscetti, Franco Darvas, Martin Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples |
title | Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples |
title_full | Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples |
title_fullStr | Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples |
title_full_unstemmed | Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples |
title_short | Cross species application of quantitative neuropathology assays developed for clinical Alzheimer’s disease samples |
title_sort | cross species application of quantitative neuropathology assays developed for clinical alzheimer’s disease samples |
topic | Technical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735310/ https://www.ncbi.nlm.nih.gov/pubmed/31528297 http://dx.doi.org/10.1080/20010001.2019.1657768 |
work_keys_str_mv | AT urfersilvanr crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT latimercaitlins crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT ladigeswarren crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT keenecdirk crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT benbowsarah crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT harrisonbenjamin crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT promislowdanielel crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT kaeberleinmatt crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT kraemerbrianc crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT wangadrienne crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT guscettifranco crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples AT darvasmartin crossspeciesapplicationofquantitativeneuropathologyassaysdevelopedforclinicalalzheimersdiseasesamples |